Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | TYMP | P19971 | 3/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CCR10 | P46092 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367339 | 1.00 | KMT2A (0.59) | KMT2ALMNATHRBCYP2C19CA12 | |
| [18F]Fluoromisonidazole SCHEMBL13020421 | 0.88 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19CA12 | |
| Fluoromisonidazole SCHEMBL368122 | 0.88 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19CA12 | |
| [18F]Fluoromisonidazole SCHEMBL18401354 | 0.88 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19CA12 | |
| [18F]Fluoromisonidazole SCHEMBL17022268 | 0.88 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL15899144 | 0.85 | KMT2A (0.56) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL12396375 | 0.84 | KMT2A (0.78) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL2358150 | 0.82 | KMT2A (0.71) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL14042973 | 0.81 | KMT2A (0.47) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL12427874 | 0.81 | KMT2A (0.47) | KMT2ALMNATHRBCYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118662796-A | Systems and methods for bio-adaptive radiation therapy | 反射医疗公司 | 2024-09-20 | — | — | CN | claimed |
| CN-118662796-A | Systems and methods for bio-adaptive radiation therapy | 反射医疗公司 | 2024-09-20 | — | — | CN | disclosed |
| EP-4344736-A2 | METHODS FOR CALCULATING BOUNDED DOSE-VOLUME HISTOGRAMS (DVH) FOR EVALUATING A TREATMENT PLAN | RefleXion Medical, Inc. (US) | 2024-04-03 | — | — | EP | disclosed |
| EP-3641884-B1 | METHODS FOR CALCULATING BOUNDED DOSE-VOLUME HISTOGRAMS (DVH) FOR EVALUATING A TREATMENT PLAN | REFLEXION MEDICAL INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-10357577-B2 | Bacterial nitroreductase enzymes and methods relating thereto | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-07-23 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20130295011-A1 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | VICTORIA LINK LIMITED (NZ) | 2013-11-07 | — | — | US | disclosed |
| US-20130295011-A1 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | VICTORIA LINK LIMITED (NZ) | 2013-11-07 | — | — | US | disclosed |
| EP-2593796-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | Auckland Uniservices Limited (NZ) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012008860-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | KMT2A 2366/4885LMNA 4469/4885THRB 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.